Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Tempest Therapeutics ( (TPST) ) is now available.
Tempest Therapeutics entered into a securities purchase agreement on March 20, 2026 with two institutional investors and Factor Bioscience for a private placement of 462,964 common shares and pre-funded warrants for up to 462,963 additional shares, each unit accompanied by Series A and Series B warrants. The transaction, expected to close around March 23, 2026, is set to raise about $2.0 million in gross proceeds, with up to $4.0 million more possible from warrant exercises, and includes obligations to seek shareholder approval for warrant share issuance and to register the resale of the new securities with the SEC within set timelines.
The deal structures Series A and B warrants with five-year and two-year terms respectively, exercisable after shareholder approval and registration effectiveness, at an exercise price of $2.16 per share, while the pre-funded warrants are immediately exercisable at $0.001 per share. Tempest has also agreed to a 30-day lock-up on additional equity issuances after registration effectiveness and to pay H.C. Wainwright & Co. tiered placement fees, underscoring a relatively small but structured capital raise that modestly strengthens liquidity while limiting near-term dilution and supporting ongoing corporate operations.
The most recent analyst rating on (TPST) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing losses, and significant cash burn with a shrinking equity cushion). Technicals remain soft with price below key longer-term averages and negative MACD. Corporate events are mixed (Nasdaq compliance risk vs. governance approvals), and valuation metrics offer limited support due to negative earnings and no dividend.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies, with its common stock traded publicly and its financing activities centered on private placements of equity and warrant securities to institutional and strategic investors. The company deploys such capital primarily for working capital and general corporate purposes as it advances its clinical and operational programs in the healthcare sector.
Average Trading Volume: 103,734
Technical Sentiment Signal: Sell
Current Market Cap: $30.87M
For an in-depth examination of TPST stock, go to TipRanks’ Overview page.